Finch Therapeutics
200 Inner Belt Road
Suite 400
Somerville
Massachusetts
02143
United States
Website: http://finchtherapeutics.com
Email: info@finchtherapeutics.com
About Finch Therapeutics
Finch Therapeutics is a mission-driven biopharmaceutical company that aims to develop novel microbial therapies serving patients with serious and unmet medical needs. Founded by data scientists, clinicians, and microbiologists from MIT and OpenBiome, Finch uses machine-learning algorithms informed by high-throughput molecular data to reverse engineer successful experiences with fecal transplantation. Through this and other clinical datasets, Finch identifies the microbes that drive desirable clinical outcomes, and develops therapies that deliver those microbial communities to patients. FIN-403 is both Finch’s lead clinical program and a valuable tool for its broader human-first discovery strategy.YEAR FOUNDED:
2014
LEADERSHIP:
CEO: Mark Smith
COO: Andrew Noh
CFO: Susan Clancy
JOBS:
Please click here for Finch job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
65 articles about Finch Therapeutics
-
The FDA asked Finch to pause enrollment for the trial on CP101 in recurrent C. difficile infection, pending details on how SARS-CoV-2 donor samples will be shipped to the vendor.
-
BioSpace Movers & Shakers, Feb. 11
2/11/2022
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers. -
Finch Therapeutics Announces Additions to Senior Leadership Team
2/10/2022
Finch Therapeutics Group, Inc. today announced the appointment of Bryan Gillis, MBA, to Chief Technology Officer, Alka Batycky, PhD, to Chief Development Officer, and Howard Franklin, MD, MBA, to Senior Vice President, Late-Stage Development and Gastrointestinal (GI) Therapeutic Area Lead.
-
Bayer isn't the only company to announce changes to its leadership team this morning. Editas, Biogen, Takeda, Merck and Vedere Bio also announced leadership changes.
-
Finch Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
1/4/2022
Finch Therapeutics Group, Inc. today announced that Mark Smith, PhD, Chief Executive Officer, will present a corporate overview at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:45 a.m.
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
BioSpace Movers & Shakers, Nov. 12
11/12/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Finch Therapeutics to Participate in Upcoming Investor Conferences
11/11/2021
Finch Therapeutics Group, Inc. today announced that Mark Smith, PhD, Chief Executive Officer, will participate virtually in two upcoming investor conferences: Jefferies London Healthcare Conference
-
Finch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
11/10/2021
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, reported financial results for the third quarter ended September 30, 2021 and provided business updates.
-
Finch Therapeutics Announces Transition of Chief Medical Officer
11/10/2021
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced that Zain Kassam, MD, MPH has elected to step down as Chief Medical Officer in order to return to Canada to attend to a family health matter.
-
Clinical Catch-Up: October 25-29
11/1/2021
Yet another busy week for clinical trial news. Here’s a look. -
Finch Therapeutics to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
10/12/2021
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced that Mark Smith, PhD, Chief Executive Officer, will present at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Tuesday, October 19, 2021.
-
BioSpace Movers & Shakers, Oct. 8
10/8/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors
10/5/2021
Finch Therapeutics Group, Inc. today announced that Samuel Allen (Al) Hamood has joined Finch’s Board of Directors. Mr. Hamood is an accomplished executive with over 30 years of experience in finance
-
BioSpace Movers & Shakers, Sept. 10
9/10/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer
9/8/2021
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced the appointment of Marc Blaustein as Chief Operating Officer.
-
Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
9/7/2021
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced that Mark Smith, PhD, Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021.
-
Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
8/10/2021
Finch Therapeutics Group, Inc. today reported financial results for the second quarter ended June 30, 2021 and provided a business update.
-
Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program
8/10/2021
Finch Therapeutics Group, Inc. today announced that Takeda Pharmaceutical Company Limited (“Takeda”) has elected to accelerate the transition of development responsibility for the FIN-524 ulcerative colitis development program.
-
Finch Therapeutics Added to Russell 2000 and Russell 3000 Indexes
6/28/2021
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced that it was added to the Russell 2000 and Russell 3000 Indexes as part of the 2021 Russell indexes annual reconstitution that took effect after the market close on June 25, 2021.